Abstract:Background: Drug-induced liver injury (DILI) often presents with diverse clinical phenotypes even when the same causative agent is involved, while some drugs cause a more distinct signature (e.g., acute hepatocellular injury by acetaminophen; acute cholestasis by anabolic steroids). The clinical phenotype diversity associated with most causal drugs may be partly explained by multi-phasic interplays between drug and host properties. We aimed to explore and characterize drug-host interplay in initial biochemical presentations in a large well-characterized Spanish DILI patient population. Methods: We analyzed 695 cases enrolled in the Spanish DILI registry. Information on demography, causal drugs, comorbidities, co-medications, and clinical manifestations including initial biochemical presentations, was collected at the time of study enrollment. Information on causative drug properties was obtained from the literature as well as the Liver Toxicity Knowledge Base. Cases manifested as mixed biochemical injury pattern were excluded from this analysis. Logistic regression model (hepatocellular vs. cholesteric injury) was used to assess each host/drug factor pair along with their interaction term. Once a statistically significant interaction term was identified, separate logistic regression models were applied to determine whether a divergent relationship between liver injury and drug property exists among host factor subgroups. Results: A total of 68 host factors and 71 drug properties were analyzed. Among 4828 host/drug factor pairs assessed, 26 pairs were identified as statistically significant interactions. The identified pairs included, but were not limited to, age-hepatic metabolism, hyperlipidemia-reactive metabolite, and allergic records-drug electronegativity. Further subgroup analyses revealed that older age (>60 years) was associated with cholestatic injury only for drugs which are not significantly metabolized in the liver (OR=3.9, 95%CI=2.0-7.7, p=0.0001), such as amoxicillin-clavulanate, nitrofurantoin or methotrexate, but not for drugs with significant hepatic metabolism (OR=1.6, 95%CI=0.9-2.9, p=0.09), such as isoniazid or flutamide.Conclusions: Data-mining analysis using logistic regression models with an interaction term identified multiple potential combinations of host/drug factors, which may interact and modify initial biochemical presentations in DILI. The identified interactions may aid in better understanding the heterogeneity of clinical presentations in DILI cases. Further methodological implementation to discover latent associations among multiple factors (>2 factors) are warranted. Funding: AEMPS, FEDER-PI15/01440, CIBERehd-ISCIII

Drug interaction with Udp-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury

The Liver Toxicity Knowledge Base (LKTB) and Drug-Induced Liver Injury (DILI) Classification for Assessment of Human Liver Injury

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury

Insights into Mechanisms and Severity of Drug-Induced Liver Injury Via Computational Systems Toxicology Approach.

Validating Disease Associations of Drug-Metabolizing Enzymes through Genome-Wide Association Study Data Analysis

Metabolomics and Cytokine Analysis for Identification of Severe Drug-Induced Liver Injury.

Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases

Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential

Molecular mechanisms involved in drug-induced liver injury caused by urate-lowering Chinese herbs: A network pharmacology study and biology experiments

Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury

Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies

Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: Emerging role of gut microbiota dysbiosis

Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions

[An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury].

Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: Prediction of in vivo drug-drug interactions

Association Study of Ugt1a9 Promoter Polymorphisms with Dili Based on Systematically Regional Variation Screen in Chinese Population

Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches